The DOI matches its Crossref record.
Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection
Open accessAbstract
We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific neutralizing antibodies (nAb) within the first year of infection. In order to determine the specificity and evolution of these autologous nAbs, we examined neutralization escape in four individuals whose responses against the earliest envelope differed in magnitude and potency. Neutralization escape occurred in all participants, with later viruses showing decreased sensitivity to contemporaneous sera, although they retained sensitivity to new nAb responses. Early nAb responses were very restricted, occurring sequentially and targeting only two regions of the envelope. In V1V2, limited amino acid changes often involving indels or glycans, mediated partial or complete escape, with nAbs targeting the V1V2 region directly in 2 cases. The alpha-2 helix of C3 was also a nAb target, with neutralization escape associated with changes to positively charged residues. In one individual, relatively high titers of anti-C3 nAbs were required to drive genetic escape, taking up to 7 weeks for the resistant variant to predominate. Thereafter titers waned but were still measurable. Development of this single anti-C3 nAb specificity was associated with a 7-fold drop in HIV-1 viral load and a 4-fold rebound as the escape mutation emerged. Overall, our data suggest the development of a very limited number of neutralizing antibody specificities during the early stages of HIV-1 subtype C infection, with temporal fluctuations in specificities as escape occurs. While the mechanism of neutralization escape appears to vary between individuals, the involvement of limited regions suggests there might be common vulnerabilities in the HIV-1 subtype C transmitted envelope.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Gray, E. S., Madiga, M. C., Hermanus, T., Moore, P. L., Wibmer, C. K., Tumba, N. L., Werner, L., Mlisana, K., Sibeko, S., Williamson, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00198-11 · Cited by 466
Self-citationIncreased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Rolland, M., Edlefsen, P. T., Larsen, B. B., Tovanabutra, S., Sanders-Buell, E., Hertz, T., deCamp, A. C., Carrico, C., Menis, S., Magaret, C. A., et al. (2012) · Nature · doi:10.1038/nature11519 · Cited by 417
The Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Metadata
- Authors
- Moore, P. L., Ranchobe, N., Lambson, B. E., Gray, E. S., Cave, E., Abrahams, M.-R., Bandawe, G., Mlisana, K., Abdool Karim, S. S., Williamson, C., Morris, L., & the CAPRISA 002 study and the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI)
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-09-18
- Volume
- 5
- Issue
- 9
- Pages
- e1000598
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2085166312
- Cited by
- 233
- References
- 0
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. https://app.cochat.ai/papers/10.1371/journal.ppat.1000598
- The paper
- Moore, P. L., Ranchobe, N., Lambson, B. E., Gray, E. S., Cave, E., Abrahams, M.-R., Bandawe, G., Mlisana, K., Abdool Karim, S. S., Williamson, C., Morris, L., & the CAPRISA 002 study and the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). (2009). Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. PLoS Pathogens. https://doi.org/10.1371/journal.ppat.1000598
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.